Humacyte, Inc.
HUMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $598 | $294 | $217 | $290 |
| - Cash | $45 | $80 | $150 | $218 |
| + Debt | $17 | $57 | $50 | $51 |
| Enterprise Value | $570 | $271 | $118 | $123 |
| Revenue | $0 | $0 | $2 | $1 |
| % Growth | – | -100% | 23.9% | – |
| Gross Profit | -$7 | -$77 | -$7 | -$60 |
| % Margin | – | – | -427.5% | -4,756.8% |
| EBITDA | -$132 | -$96 | -$76 | -$73 |
| % Margin | – | – | -4,879.7% | -5,777.3% |
| Net Income | -$149 | -$111 | -$12 | -$26 |
| % Margin | – | – | -764.5% | -2,096.4% |
| EPS Diluted | -1.26 | -1.07 | -0.12 | -0.66 |
| % Growth | -17.8% | -791.7% | 81.8% | – |
| Operating Cash Flow | -$98 | -$73 | -$71 | -$81 |
| Capital Expenditures | -$2 | -$2 | -$1 | -$0 |
| Free Cash Flow | -$100 | -$76 | -$72 | -$81 |